

## Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

### Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
G	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: March 26, 2013 \_\_\_\_\_

State Party to the Convention: Finland \_\_\_\_\_

Date of ratification/accession to the Convention: February 4, 1974 \_\_\_\_\_

National point of contact: Aleksi Vakkuri / MFA \_\_\_\_\_

## Confidence-Building Measure "A"

### Form A, part 1 (i)

No maximum containment laboratory exists in Finland.

### Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents<sup>1</sup> on a State Party's territory:

Biosafety level 3 <sup>2</sup>	<input checked="" type="checkbox"/> yes / no
Biosafety level 2 <sup>3</sup> (if applicable)	yes / no

Any additional relevant information as appropriate:

Additional information specific to each laboratory working with biological agents at BSL2/BSL3 level follows from these organisations: Centre for Biothreat Preparedness, National Institute of Health and Welfare (THL), University of Helsinki; *i*) Yersinia Research Laboratory, *ii*) Department of Virology, *iii*) Institute of Biotechnology, Finnish Food Safety Authority (Evira), and Finnish Defence Forces Technical Research Centre (PVTT).

---

<sup>1</sup> Microorganisms pathogenic to humans and/or animals

<sup>2</sup> In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

<sup>3</sup> In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

## Exchange of Data on Research Centres and Laboratories #1

**1. Name(s) of the Facility**

Centre for Biothreat Preparedness

**2. Responsible public or private organization or company**

Centre for Military Medicine, Finnish Defence Forces under the Ministry of Defence and the National Institute for Health and Welfare (THL) under Ministry of Social Affairs and Health.

**3. Location and postal address**

Tukholmankatu 8 A, FI-00290 Helsinki and Mannerheimintie 166, FI-00300 Helsinki.

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**

The Centre is financed jointly by the Finnish Defence Forces and National Institute for Health and Welfare (THL).

**5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**

There are no BSL-4 units at the Centre.

**6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**

The Centre for Biothreat Preparedness started its activities in 2005. During 2012, the Centre developed rapid PCR detection assays for selected microbial agents.

**If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents<sup>4</sup> on a State Party's territory:**

Biosafety level 3	yes
-------------------	-----

---

<sup>4</sup> Microorganisms pathogenic to humans and/or animals

## Exchange of Data on Research Centres and Laboratories #2

**1. Name(s) of the Facility**

National Institute for Health and Welfare (THL), bacteriological and virological laboratories.

**2. Responsible public or private organization or company**

National Institute for Health and Welfare (THL) under Ministry of Social Affairs and Health.

**3. Location and postal address**

Mannerheimintie 166  
FI-00300 Helsinki

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**

Funding from the Ministry of Social Affairs and Health and large variety of external research funding.

**5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m<sup>2</sup>)**

There are no BSL-4 laboratories or other units at this containment level.

**6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**

7. Clinical and environmental microbiological research and reference laboratory facilities in Helsinki, Turku, Kuopio and Oulu. Working mainly with ordinary occurring endemic and epidemic bacteria and viruses with main emphases on vaccine preventable diseases, enteric pathogens, zoonoses, tuberculosis spp, enteroviruses, polioviruses, influenza (including 2009 pandemic influenza H1N1), HIV, hepatitis viruses and environmental fungi and bacteria causing human health problems. The Institute manages regional influenza and polio laboratory facilities. The Institute is in charge of biothreat preparedness in public health context. National focal point for IHR started June 2007.

**If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents<sup>5</sup> on a State Party's territory:**

Biosafety level 3	yes
-------------------	-----

**Any additional relevant information as appropriate:**

Two BSL-3 level laboratories: 120m<sup>2</sup> in Helsinki and 80m<sup>2</sup> in Turku.

---

<sup>5</sup> Microorganisms pathogenic to humans and/or animals

## Exchange of Data on Research Centres and Laboratories #3

**1. Name(s) of the Facility**

Yersinia Research Laboratory

**2. Responsible public or private organization or company**

University of Helsinki

**3. Location and postal address**

Department of Bacteriology and Immunology  
Haartman Institute, University of Helsinki  
Haartmaninkatu 3  
P.O Box 21  
FI-00014 University of Helsinki  
Helsinki, Finland

Yersinia-research home page: <http://www.helsinki.fi/yersinia/>

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**

Special state subsidy (EVO) for health science research in Finland, Centre for Military Medicine.

**5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**

No BSL-4 laboratories.

**6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**

The research is focused on genetics and biosynthesis of lipopolysaccharide (LPS) of *Yersinia pestis*, as well as on the role of LPS in virulence. Molecular evolution studies elucidate the relationships between the species of the genus *Yersinia*. Research work is also conducted on the identification of *Y. pestis* specific bacteriophage receptors.

**If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents<sup>6</sup> on a State Party's territory:**

---

<sup>6</sup> Microorganisms pathogenic to humans and/or animals

Biosafety level 3	no
Biosafety level 2 (if applicable)	<b>yes</b>

**Exchange of Data on Research Centres and Laboratories #4:**

**1. Name(s) of the research centre and/or laboratory**  
Department of Virology

**2. Responsible public or private organization or company**  
University of Helsinki

**3. Location and postal address**  
P.O. Box 21  
Haartman Institute  
00014 University of Helsinki

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**  
In 2012 funding was received from Helsinki University Hospital EVO-fund, University of Helsinki, National Technology Agency of Finland, Academy of Finland, and Sigrid Jusélius Foundation. A project on detection of biothreat agents (RNA viruses) has been funded by the Centre for Military Medicine (Ministry of Defence), also on-going (funded previous and the next year) a project on haemorrhagic fever diagnostic by the Finnish Advisory Board for Defence.

**5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**  
There are no BSL-4 laboratories.

**6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**  
The Helsinki University Viral Zoonoses Group (HUVZG) conducts research on virology, cell biology, ecology and epidemiology of zoonotic viruses, especially hantaviruses and certain other rodent-borne and arboviruses occurring in Northern Europe. The research group operates within the Faculty of Medicine, Haartman Institute Department of Virology, and partially the Department of Veterinary Biosciences at the Veterinary Faculty. There is a BSL-3 facility in both faculties. The Viral Zoonoses group is connected to the diagnostic laboratory of viral zoonoses at HUSLAB, Helsinki, and also acts as a WHO Collaborating Centre for Arbo- and Zoonotic Viruses. Principal investigators of the group are Alexander Plyusnin, Antti Vaheri and Olli Vapalahti.

**If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents<sup>7</sup> on a State Party's territory:**

Biosafety level 3	yes
-------------------	-----

<sup>7</sup> Microorganisms pathogenic to humans and/or animals

**Exchange of Data on Research Centres and Laboratories #5**

- 1. Name(s) of the research centre and/or laboratory**  
Institute of Biotechnology
- 2. Responsible public or private organization or company**  
University of Helsinki
- 3. Location and postal address**  
Institute of Biotechnology  
P.O. Box 56 (Viikinkaari 9)  
00014 University of Helsinki
- 4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**  
The funding was received from EU FP7 via the “Integrated Chikungunya Research” consortium.
- 5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**  
There are no BSL-4 laboratories.
- 6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
7. The research group carries out alphavirus research at the Institute of Biotechnology, University of Helsinki. The research focuses on the alphavirus (Semliki Forest virus, Sindbis virus and Chikungunya virus) replication mechanisms and antiviral development. Small molecular-weight inhibitors are searched against Chikungunya virus. The Chikungunya virus research is conducted in the BSL-3 laboratory at the Department of Veterinary Biosciences at the Veterinary Faculty.

**If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents<sup>8</sup> on a State Party’s territory:**

Biosafety level 3	yes
-------------------	-----

---

<sup>8</sup> Microorganisms pathogenic to humans and/or animals



## Exchange of Data on Research Centres and Laboratories #6

**1. Name(s) of the Facility**

Finnish Food Safety Authority (Evira)

**2. Responsible public or private organization or company**

Finnish Food Safety Authority under the Ministry of Agriculture and Forestry

**3. Location and postal address**

Mustialankatu 3  
FI-00790 Helsinki

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**

Financing from the Ministry of Agriculture and Forestry

**5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m<sup>2</sup>)**

None

**6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**

Diagnostics, surveillance and reference laboratory activities of animal diseases, zoonotic agents and foodborne pathogens, for example rabies, avian influenza, swine influenza (including pandemic H1N1 in pigs), Newcastle disease, foot and mouth disease, classical swine fever, anthrax, tuberculosis, verotoxic *E. coli*.

**If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents<sup>9</sup> on a State Party's territory:**

Biosafety level 3	yes
-------------------	-----

**Any additional relevant information as appropriate:**

Evira has six containment level 3+ laboratories, total size 473,5m<sup>2</sup> in addition to biosafety level 2 laboratories.

---

<sup>9</sup> Microorganisms pathogenic to humans and/or animals

## Exchange of Data on Research Centres and Laboratories #7

**1. Name(s) of the Facility**

Finnish Defence Forces Technical Research Centre (PVTT)

**2. Responsible public or private organization or company**

Finnish Defence Forces Technical Research Centre (PVTT), Finnish Defence Forces under the Ministry of Defence.

**3. Location and postal address**

P.O. Box 5 (Paroistentie 20)  
FI-34111 Lakiala  
Finland

**4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**

Finnish Defence Forces

**5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**

No BSL-4 laboratories.

**6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**

The objective of the research work has been in the development of identification methods for biowarfare microbes and toxins. A deployable BC-field laboratory participated in international military exercises. All biodefence research and exercises were carried out with non-pathogenic strains, or otherwise harmless microbes, therefore also the deployable BC-field laboratory was used only at BSL-2 level.

**If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents<sup>10</sup> on a State Party's territory:**

Biosafety level 3	no
Biosafety level 2 (if applicable)	yes

**Any additional relevant information as appropriate:**

The deployable BC laboratory was used at BSL2 level during 2012.

<sup>10</sup> Microorganisms pathogenic to humans and/or animals

## **Part 2 Exchange of information on national biological defence research and development programmes**

### **Form A, part 2 (i)**

#### **National biological defence research and development programmes Declaration**

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

**yes** / no

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

### **Form A, part 2 (ii, iii)**

#### **National biological defence research and development programmes**

The Finnish Strategy to Secure Vital Functions of Society (2003 and 2006), as well as The Security Strategy for Society (2010) have defined vital functions of Finnish society and established targets and development policies that guide each administrative branch of the government in dealing with its strategic tasks. These strategies called for co-operation between each government sector in combating against new threats towards society. According to the Government Reports on Finnish Security and Defence Policy of 2004 and 2009, terrorism and epidemics caused by infectious diseases were listed as key threats affecting national security.

Based on the above resolutions The Centre for Biothreat Preparedness started operations in Helsinki in May 2005. The Centre combines Finnish scientific and laboratory knowhow on biological defence, as well as on biothreat assessment and preparedness. The Centre has actively sought domestic and international collaboration, especially in the field of rapid detection and identification methodologies of selected biological agents. The Centre is composed of two units: the Biological Defence Unit of the Finnish Defence Forces, and the Department of Infectious Disease Surveillance and Control at the National Institute of Health and Welfare (THL). Scientific work is carried out at a biological safety level 3 laboratory at the THL facilities. In addition, the Centre functions within the Biomedicum Helsinki Institute, where work is carried out in close contact with the CB Defence and Environmental Health Centre of the Centre for Military Medicine.

## **Confidence-Building Measure "B"**

### **Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins**

#### **Form B**

#### **Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern<sup>11</sup>**

No unusual human or animal disease outbreaks were detected.

---

<sup>11</sup> See paragraph 2 of the chapeau to Confidence-Building Measure B.

## Confidence-Building Measure "C"

### Encouragement of publication of results and promotion of use of knowledge

Beczala A, Duda KA, Skurnik M, and Holst O. 2012. The structure of the O-specific polysaccharide of the lipopolysaccharide from *Yersinia enterocolitica* serotype O:50 strain 3229. Carbohydrate Research 359: 97-101.

Białas N, Kasperkiewicz K, Radziejewska-Lebrecht J, and Skurnik M. Bacterial cell surface structures in *Yersinia enterocolitica*. AITE 60: 199-209.

Erra EO, Askling HH, Rombo L, Riutta J, Vene S, Yoksan S, Lindquist L, Pakkanen SH, Huhtamo E, Vapalahti O, Kantele A. 2012. A single dose of vero cell-derived **Japanese encephalitis (JE)** vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines. Clin Infect Dis. Sep;55(6):825-34.

Ho D, Riva R, Kirjavainen V, Jarva H, Ginström E, Blom AM, Skurnik M, and Meri S. 2012. Functional Recruitment of the Human Complement Inhibitor C4b-Binding Protein to *Yersinia pseudotuberculosis* Outer Membrane Protein Ail. J. Immunol. 188: 4450-4459.

Ho DK, Riva R, Skurnik M, and Meri S. 2012. The *Yersinia pseudotuberculosis* outer membrane protein Ail recruits the human complement regulatory protein factor H. J. Immunol. 189: 3593-3599.

Huhtamo E, Comach G, Sierra G, Camacho DE, Sironen T, Vapalahti O, Uzcátegui NY. 2012. Diversity and composition of **dengue virus** type 2 in Venezuela. Epidemiol Infect. Oct 31:1-7.

Jalava K, Sane J, Ollgren J, Ruuhela R, Rätti O, Kurkela S, Helle P, Hartonen S, Pirinen P, Vapalahti O, Kuusi M. 2012. Climatic, ecological and socioeconomic factors as predictors of **Sindbis virus** infections in Finland. Epidemiol Infect. Nov 16:1-10.

Katz A, Freiberg AN, Backström V, Holm L, Vaheri A, Flick R, Plyusnin A. 2012. Mutational analysis of positively charged amino acid residues of **Uukuniemi phlebovirus** nucleocapsid protein. Virus Res. Jul;167(1):118-23.

Kinnunen PM, Haataja T, Hemmilä H, Maatela P, Teho K, Elo M, Rajas T, Nikkari S. 2012. Mobile diagnostic **CBRN field laboratory**: NATO evaluated Finnish design. Challenge 1:14-8.

Kondakova AN, Sevillano AM, Shaikhutdinova RZ, Lindner B, Komandrova NA, Dentovskaya SV, Shashkov AS, Anisimov AP, Skurnik M, and Knirel YA. 2012. Revision of the O-polysaccharide structure of *Yersinia pseudotuberculosis* O:1a; confirmation of the function of WbyM as paratransferase. Carbohydrate Research 350: 98-102.

Kurkela S, Sane J, Deren E, Huhtamo E, Suomalainen I, Kantele A, Vapalahti O. 2012. **Chikungunya virus** as a causative agent of fever of unknown origin in Finnish travellers to tropics. J Clin Virol. Jul;54(3):289-90.

Lin XD, Guo WP, Wang W, Zou Y, Hao ZY, Zhou DJ, Dong X, Qu YG, Li MH, Tian HF, Wen JF, Plyusnin A, Xu J, Zhang YZ. 2012. Migration of norway rats resulted in the worldwide distribution of **seoul hantavirus** today. J Virol. Jan;86(2):972-81. Epub 2011 Nov 16.

- Mölsä M, Koskela KA, Rönkkö E, Ikonen N, Ziegler T, Nikkari S. 2012. Detection of **influenza A viruses** with a portable real-time PCR instrument. *J Virol Methods*. May;181(2):188-91.
- Pajunen M, Pinta E, and Skurnik M. 2012. Construction and Screening of the Transposon Insertion Library of *Yersinia enterocolitica* (YeO3-R1). *Bio-Protocol*. On-line: <http://www.bio-protocol.org/wenzhang.aspx?id=246>.
- Palonen E, Kangas S, Somervuo P, Lindström M, Fredriksson-Ahomaa M, Skurnik M, and Korkeala H. 2012. Sequencing of virulence genes shows limited genetic variability in *Yersinia pseudotuberculosis*. *Foodborne Pathog Dis*. 10: DOI: 10.1089/fpd.2012.1247.
- Pinta E, Li Z, Batzilla J, Pajunen M, Kasanen T, Rabsztyń K, Rakin A, and Skurnik M. 2012. Identification of three oligo-/polysaccharide-specific ligases in *Yersinia enterocolitica*. *Molecular Microbiology* 83: 125-136.
- Plyusnina A, Razzauti M, Sironen T, Niemimaa J, Vapalahti O, Vaheri A, Henttonen H, Plyusnin A. 2012. Analysis of complete **Puumala virus** genome, Finland. *Emerg Infect Dis*. Dec;18(12):2070-2.
- Ravanini P, Huhtamo E, Ilaria V, Crobu MG, Nicosia AM, Servino L, Rivasi F, Allegrini S, Miglio U, Magri A, Minisini R, Vapalahti O, Boldorini R. 2012. **Japanese encephalitis virus** RNA detected in *Culex pipiens* mosquitoes in Italy. *Euro Surveill*. Jul 12;17(28). doi:pii: 20221.
- Razzauti M, Plyusnina A, Niemimaa J, Henttonen H, Plyusnin A. Co-circulation of two **Puumala hantavirus** lineages in Latvia: a Russian lineage described previously and a novel Latvian lineage. *J Med Virol*. 2012 Feb;84(2):314-8. doi: 10.1002/jmv.22263.
- Sane J, Kurkela S, Levanov L, Nikkari S, Vaheri A, Vapalahti O. 2012. Development and evaluation of a real-time RT-PCR assay for **Sindbis virus** detection. *J Virol Methods*. Jan;179(1):185-8.
- Sane J, Kurkela S, Putkuri N, Huhtamo E, Vaheri A, Vapalahti O. 2012. Complete coding sequence and molecular epidemiological analysis of **Sindbis virus** isolates from mosquitoes and humans, Finland. *J Gen Virol*. Sep;93(Pt 9):1984-90.
- Sane J, Kurkela S, Desdouits M, Kalimo H, Mazalrey S, Lokki ML, Vaheri A, Helve T, Törnwall J, Huerre M, Butler-Browne G, Ceccaldi PE, Gessain A, Vapalahti O. 2012. Prolonged myalgia in **Sindbis virus** infection: case description and in vitro infection of myotubes and myoblasts. *J Infect Dis*. Aug 1;206(3):407-14.
- Sihvonen LM, Jalkanen K, Huovinen E, Toivanen S, Corander J, Kuusi M, Skurnik M, Siitonen A, and Haukka K. 2012. Strains classified as *Yersinia enterocolitica* biotype 1A represent two phylogenetic lineages by MLSA and have serotype-related differences in a serum complement killing assay. *BMC Microbiology* 12: 208.
- Skurnik M. 2012. *Yersinia* surface structures and bacteriophages. *Adv. Med. Biol. Exp.* 954:293-301.
- Skurnik M, Hyytiäinen H, Happonen L, Kiljunen S, Datta N, Mattinen L, Williamson K, Kristo P, Szeliga M, Kalin-Mänttari L, Ahola-Iivarinen E, Kalkkinen N, and Butcher S. 2012. Characterization of the genome, proteome and structure of **yersiniophage  $\phi$ R1-37**. *J. Virol*. 86: 12625-12642.
- Uzcátegui NY, Sironen T, Golovljova I, Jääskeläinen AE, Välimaa H, Lundkvist A, Plyusnin A, Vaheri A, Vapalahti O. 2012. Rate of evolution and molecular epidemiology of tick-borne encephalitis virus in Europe, including two isolations from the same focus 44 years apart. *J Gen Virol*. Apr;93(Pt 4):786-96.

## **Publications in Finnish**

Sissonen S, Rajjas T, Haikala O, Hietala H, Virri M, Nikkari S. 2012. Biologisten aseiden kieltosopimuksen uudet haasteet. Duodecim. 128(3):283-9. [**New challenges in the biological weapons convention**].

Rossow H, Kinnunen PM, Nikkari S. 2012. Botulinumtoksiini biouhka-agenssina. Duodecim;128(16):1678-84. [**Botulinum toxin as a biological weapon**].

Sissonen S, Kinnunen PM, Vakkuri A, Poutiainen S, Rajjas T, Salminen M, Nikkari S. 2012. Biouhilta turvassa? - Säädökset suojaavat työntekijää ja yhteiskuntaa. Duodecim, 128(21):2217-23. [**Safe from biothreats? Legislation protects you and society**].

## Confidence-Building Measure "E"

### Form E

#### Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures <sup>12</sup>	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(b) Exports of micro-organisms <sup>13</sup> and toxins	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(c) Imports of micro-organisms <sup>11</sup> and toxins	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(d) Biosafety <sup>14</sup> and biosecurity <sup>15</sup>	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No

#### Additional information to form E

Finland's legislation on biological weapons is based on the Biological Weapons Act 257/1975 and Decree 258/1975. Corresponding penal provisions were included in the Penal Code, chapter 11, section 7 b (Breach of the prohibition of biological weapons), with amendment 17/2003. Penal Code (39/1889) chapter 11, section 1 (War Crime), chapter 5, section 3 (Complicity in an offence) and section 6 (Abetting), chapter 34, sections 4 (Health endangerment) and 5 (Aggravated health endangerment), and chapter 34 a (Terrorist offences) are also applicable.

<sup>12</sup> Including guidelines.

<sup>13</sup> Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

<sup>14</sup> In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

<sup>15</sup> In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.



Exports of micro-organisms and toxins are regulated by the Act on the Control of Export of Dual-Use Goods (562/1996, as amended by Acts 891/2000, 884/2001 and 581/2003), Government Decree on the Control of Export of Dual-Use Goods (924/2000 as amended by Decree 924/2000) and EC Council Regulation 1334/2000. Corresponding penal provisions were incorporated in the Penal Code (39/1889), chapter 46, sections 1-3 by Acts 769/1990, 1522/1994 and 706/1997. Since 2003, the authority responsible for export controls of micro-organisms and toxins is the Ministry for Foreign Affairs (Export Control Unit).

Imports of micro-organisms and toxins are regulated by the Biological Weapons Act 257/1975 and Decree 258/1975. Transports of micro-organisms and toxins are also regulated by the EC Council Directives 94/55/EEC and 96/49/EEC, the Communicable Diseases Act 583/1986 (as amended), section 33; Communicable Diseases Decree 786/1986 (as amended); Act on the Transport of Dangerous Goods (719/1994 as amended) and related decrees, Act on Protecting Plant Health (702/2003), section 7, and related decrees, Act on Animal Diseases (55/1980 as amended) and related decrees, Act on Veterinary Border Control (1192/1996 as amended) and related decrees. The corresponding penal provisions are included in the Penal Code (39/1889 as amended), chapter 44, section 2 (Health protection violation), chapter 44, section 13 (Transport of dangerous substances offence) and chapter 46, section 4 (Smuggling).

Biosafety is regulated by the Occupational Safety and Health Act (738/2002), as amended by the Government Decision for Protecting Employees from Work-related Threat Caused by Biological Agents (1155/1993), and Decision of the Ministry of Social Affairs and Health on the Classification of Biological Agents (921/2010). Furthermore, regulations concerning biosafety are included in the Communicable Diseases Act (583/1986) and Decree (786/1986), as well as Gene Technology Act (377/1995) and Government Decree on Gene Technology (928/2004). These biosafety regulations partly overlap with biosecurity; no specific biosecurity legislation exists.

## **Confidence-Building Measure "F"**

### **Form F**

#### **Declaration of past activities in offensive and/or defensive biological research and development programmes**

Nothing to declare.

## **Confidence-Building Measure "G"**

### **Form G**

#### **Declaration of vaccine production facilities**

There are no vaccine production facilities in Finland.